Immunome, Inc. (IMNM)
Immunome, Inc. operates in the Biotechnology industry of the Healthcare sector, headquartered in Bothell, WA, US. The stock last traded at $17.99, down 1.48% on the session, giving a market capitalisation of $2.12B. On trailing twelve-month figures it carries a trailing P/E of -7.08, a net margin of 0.0%. Its beta of 2.13 implies it has historically moved more than the broad market.
Immunome, Inc., a biotechnology company, engages in the discovery, design, development, manufacturing, and commercialization of antibody-drug conjugates and other oncology therapeutics in the United States. The company develops clinical asset comprising Varegacestat, a gamma secretase inhibitor that is in Phase 3 clinical trial for the treatment of desmoid tumors; and IM-1021, a receptor tyrosine kinase-like orphan receptor 1 antibody-drug conjugate (ADC), which is in Phase 1 clinical trial. It is also developing preclinical assets, including IM-3050, a fibroblast activation protein targeted radioligand therapy; and solid tumor ADC drug candidates, such as IM-1617, IM-1340, and IM-1335. Immunome, Inc. was incorporated in 2006 and is based in Bothell, Washington.
Immunome, Inc. is most often compared with the following Healthcare names: